Rapidly progressive respiratory failure after helminth larvae ingestion

Therapeutic ingestion of parasitic organisms has gained interest among patients with autoimmune disease as a potential immune-modulating therapy, though rigorous clinical studies of this approach are lacking. Parasitic infections have known pulmonary complications such as Löffler’s syndrome, an acute eosinophilic pneumonitis precipitated by parasitic infection. It is characterized by self-limiting pulmonary symptoms, transient radiographic changes in lung fields, and peripheral blood eosinophilia. In rare occasions, large helminthic burden or underlying pulmonary disease can predispose to prolonged eosinophilic pulmonary inflammation [1]. To our knowledge, there are no reported cases of this syndrome occurring due to an intentional ingestion of parasitic organisms. Here, we present a case of rapidly progressive respiratory decline and right heart failure in a patient who self-administered parasitic organisms in an effort to treat her autoimmune disease.

A 45-year-old woman presented to pulmonary clinic for evaluation of worsening dyspnea, cough, and hypoxemia. Her medical history was significant for limited cutaneous systemic sclerosis (lcSSc), pulmonary arterial hypertension (PAH), and interstitial lung disease (ILD) (Fig. 1A). She had no history of atopy or food allergies and used an albuterol inhaler as needed. PAH had been diagnosed seven years prior to presentation when she had a reported pulmonary artery (PA) pressure of 80/39 mmHg, mean PA pressure of 56 mmHg, pulmonary capillary wedge pressure (PCWP) of 12 mmHg, and cardiac output by thermodilution of 3.17 L/min. Her pulmonary function tests (PFTs) at that time showed a forced vital capacity (FVC) of 3.06 L (75% predicted) and a diffusing capacity for carbon monoxide (DL_CO) of 19.61 mL/min/mm Hg (66% predicted). Per her medical records and history, the patient had been treated with dual therapy (tadalafil and macitentan) for PAH and was subsequently able to wean from oxygen supplementation that she had previously required, indicating a therapeutic response. Her ILD was considered mild, and she did not require supplemental oxygen at rest or with exertion. She was treated with mycophenolate mofetil for a year after her initial diagnosis, but the patient discontinued this medication about 6 years prior to presentation due to fear of reactivating remote Lyme infection after she had read about chronic Lyme disease on the internet. The patient had been stable on her regimen of tadalafil and macitentan until 3 months prior to presentation when she began to experience rapidly progressive dyspnea and new onset hypoxemia. Right heart catheterization (RHC) revealed that her PAH had worsened with a mean PA pressure of 72 mmHg and a new drop in cardiac index (1.7 L/min/m²), requiring initiation of subcutaneous treprostinil.

In the clinic, patient appeared to be in mild respiratory distress with a respiratory rate of 24 breaths per minute, and she required 6–8 L/min of oxygen via nasal cannula to maintain saturations above 90%. She was tachycardic (104 beats/min) with a loud second heart sound, jugular venous distension, and severe lower extremity pitting edema up to her thighs. Auscultation of the chest revealed bibasilar rales. Dermatologic exam was notable for scattered telangiectasias over her face, arms, and hands.

Complete blood count showed leukocytosis (13.5 × 10³/uL) with 10% eosinophils (absolute count of 0.98 × 10³ cells/uL). Of note, prior blood counts from 2017 had shown normal eosinophil counts (291 × 10³ cells/uL). Basic metabolic profile was significant for an elevated creatinine (1.31 mg/dL) but was otherwise normal. Serum brain natriuretic peptide level was elevated at 578 ng/L. IgE was also elevated at 1372.9 IU/mL, and IgG antibodies to Strongyloides were detected. Multiple stool analyses were negative for ova and parasites. PFTs at that time revealed an FVC of 2.03 L (49% predicted), a decline of over 1.0 L since her prior testing; complete testing was not possible due to her respiratory symptoms.

High resolution computed tomography (HRCT) of the chest showed worsened subpleural reticulations, traction bronchiectasis, and diffuse ground glass opacities suggesting chronic pulmonary fibrosis in a pattern consistent with non-specific interstitial pneumonia. The patient’s CT scan revealed progressive ILD and showed new diffuse ground glass opacities compared imaging from four years prior (Fig. 1A–D). There were also signs of decompensated right heart failure, including markedly enlarged dilated right heart chambers, pericardial effusion, and flattening of the interventricular septum (Fig. 1E). Though some of the ground glass opacities could have been consistent with pulmonary edema or parenchymal inflammation, additional areas had tract-like abnormalities leading to pleural edge, atypical for either of those entities [2] and not conforming to normal pulmonary vasculature (Fig. 1D).

Immediately after her disclosure of the ingestion of parasites, the patient was treated with albendazole and corticosteroids for presumed Löffler’s syndrome with transient improvement in her dyspnea and hypoxemia. However, due to progressive hypoxemia and signs of decompensated right heart failure on her examination at her outpatient visit, she was admitted to the hospital.

Transthoracic echocardiogram revealed preserved left ventricular function but severely dilated right sided chambers, with a right ventricular systolic pressure estimated at 90 mmHg. Repeat RHC revealed persistently elevated mean PA pressure of 73 mmHg, worsened PCWP of 17 mmHg, and elevated pulmonary vascular resistance of 11.5 Wood units. Due to rapid decompensation and severity of hypoxemia, bronchoscopy was not able to be performed.

Respiratory failure progressed, with the development of refractory hypoxemia and right heart failure that did not respond to aggressive medical therapy in the intensive care unit, including intravenous diuresis and treprostinil as well as inhaled epoprostenol. She was emergently evaluated for lung transplantation but was not offered listing due to her comorbidities, which included severe esophageal dysmotility and renal dysfunction. Her respiratory status continued to deteriorate despite aggressive medical intervetion, and the patient decided to transition to comfort-focused care. She passed away shortly thereafter, and post-mortem examination was declined by her family.

After self-administered helminth ingestion, our patient experienced rapidly progressing respiratory failure that may have been multi-factorial, due to worsening pulmonary hypertension and right heart failure, but also with evidence of lung parenchymal abnormalities on imaging consistent with increased inflammation after parasite exposure.

The term “Löffler’s syndrome” refers to pulmonary eosinophilia due to transpulmonary passage of helminth larvae. Several helminths, including Ascaris (A. lumbricoides, A. suum), hookworms (Ancylostoma duodenale, Necator americanus), and Strongyloides stercoralis reach the lungs hematogenously during their normal life cycle [3]. These organisms penetrate from the small alveolar vessels to the alveolar sac and tracheobronchial tree, later swallowed with sputum, thereby enter gastrointestinal tract. Transient radiographic changes in lung fields with associated peripheral blood eosinophilia due to helminthic infection, specifically Ascaris, were first described by Löffler in 1932 [4]. Ascaris is the most common cause of Löffler’s syndrome. Migrating hookworms and Strongyloides are less likely to cause pulmonary eosinophilia and symptoms in immunocompetent hosts.

Patients present with dry cough and substernal discomfort that starts about two weeks after ingestion of eggs or cutaneous penetration of larvae [5]. Fever, dyspnea, wheezing and blood-tinged sputum are also common symptoms. This is usually self-limiting in immunocompetent hosts [6], and symptoms subside in 5–10 days, but can last for more than a month [7, 8]. In rare occasions, when large numbers of larvae are released, heavy hematogenous seeding of helminth larvae can result in lung deposition and prolonged eosinophilic pulmonary inflammation [3]. In addition, Strongyloides have unique life cycle with an ability of continuous autoinfection of the human host [3, 5]. This can result in chronic pneumonitis with pulmonary symptoms and radiographic abnormalities.

Eosinophilia is usually present in association with pulmonary symptoms, and IgE levels may be increased [8]. Eosinophils and Charcot-Leyden crystals can be found in sputum or bronchoalveolar lavage (BAL) fluid [9]. Definitive diagnosis can be made by finding Ascaris, hookworm, or Strongyloides larvae in the respiratory secretions or BAL fluid [1, 5]. Serologic testing for detection of IgG antibodies is available, but specificity is low due to cross-reactivity with filarial species and nematodes [1, 5]. At the time of pulmonary manifestations, stool examinations for ova and larvae are usually negative [5]. Chest imaging can show transient migratory pulmonary opacities [4, 5]. Computed tomography of the chest usually demonstrates peripherally based nodules with a halo of ground glass attenuation. Ground glass opacities are also commonly observed.

Management of Löffler’s syndrome is primarily supportive. Anthelminthic treatment is warranted for suspected or confirmed hookworm or Strongyloides infection regardless of host’s immune status. Albendazole and mebendazole are the first-line antihelminthic drugs for hookworm [8]. If severe pneumonitis is present, systemic glucocorticoids are administered. Before initiating glucocorticoids, Strongyloides infection should be ruled out by examination of sputum and stool to prevent hyper-infection syndrome [1]. Löffler’s syndrome is usually mild and self-limiting disease in immunocompetent hosts [1, 6]. In immunocompromised patients more severe forms of Loffler’s syndrome were reported, mostly due to Strongyloides hyper-infection syndrome [1, 10, 11].

Though ingestion of helminth organisms risks infection, therapeutic ingestion of helminths has been investigated as a potential treatment for autoimmune diseases such as rheumatoid arthritis, psoriasis, multiple sclerosis, Crohn’s diseases, ulcerative colitis, and celiac disease [12, 13]. Although phase I studies suggest that helminth therapy may delay the relapse of Crohn’s disease, it is not an approved therapy for this or any autoimmune disease [14]. Helminth therapy has been associated with reduced disease scores in multiple sclerosis, though significant adverse events were associated with its use in trials [15]. Investigators have hypothesized that administration of helminths could improve autoimmune diseases through immunomodulatory effects, though its use outside of a clinical trial setting is not recommended [15, 16]. Some authors have suggested that helminth extracts may be a safer alternative to ingestion of live organisms, as it would eliminate the risk of infectious complications [15].

To our knowledge, this is the first reported case of rapidly progressive, fatal respiratory failure after self-administration of helminth larvae. It highlights the potential risk of experimental helminth therapy in patients with underlying respiratory disease. This is especially important given the considerable attention to and discussion about helminth therapy on patient-directed forums and social media [17‐19].